Low Dose Rosuvastatin Plus Ezetimibe Versus High-dose Rosuvastatin in AMI
Status:
Not yet recruiting
Trial end date:
2024-07-01
Target enrollment:
Participant gender:
Summary
Combination therapy of rosuvastatin 5mg and ezetimibe 10 mg showed similar achievement rate
in decreasing LDL cholesterol level by 50% as single use of rosuvastatin 20 mg.
This trial aims to prove non-inferiority of concomitant usage of low dose rosuvastatin and
ezetimibe among patients with acute myocardial infarction who went through percutaneous
coronary intervention at decreasing major adverse cardiac events compared to the efficacy of
single use of high dose rosuvastatin.